TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$8.99 USD
+0.98 (12.23%)
Updated May 14, 2024 04:00 PM ET
After-Market: $8.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.99 USD
+0.98 (12.23%)
Updated May 14, 2024 04:00 PM ET
After-Market: $8.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Zacks News
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -28% and 84.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 30% and 145.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of 20% and 62.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 25% and 245.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 62.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does TScan Therapeutics, Inc. (TCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 125% upside potential for TScan Therapeutics, Inc. (TCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 14.06% and 5.50%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 32.89% and 16.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -34.55% and 0.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of -27.40% and 119.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe TScan Therapeutics, Inc. (TCRX) Could Rally 147%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 147.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LabCorp (LH) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development third-quarter results are expected to reflect an increase in organic revenues in the base business.
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
by Zacks Equity Research
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.